Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more free/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: A system includes a supply receptacle defining one or more supply receptacle sidewalls and an upwardly-facing receptacle opening, a piston positioned at least partially within the supply receptacle, where the piston, the upwardly-facing receptacle opening, and the one or more supply receptacle sidewalls at least partially define an interior space of the supply receptacle, and the piston is positionable between an extended position, in which the interior space has an extended volume, and a retracted position, in which the interior space has a retracted volume that is greater than the extended volume, and a dosing hopper positioned above and in selective communication with the interior space of the supply receptacle, where the dosing hopper is structurally configured to deliver build material to the interior space.

Abstract: A system (100) includes a build area positioned along a working surface (102), a supply receptacle (110) spaced apart from the build area and defining one or more supply receptacle sidewalls and an upwardly-facing receptacle opening (114), a dosing hopper (240) positioned above and in selective communication with the supply receptacle, where the dosing hopper is structurally configured to deliver build material to an interior space (116), and a conveyance hopper (260) in communication with the dosing hopper (240).

Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.

Abstract: Aspects of the subject disclosure may include, for example, receiving, by a processing system including a processor that is operative in a first communication network, a certificate from a communication device that is operative in a second communication network, extracting, by the processing system, an identifier of the communication device from the certificate, authenticating, by the processing system, the communication device in accordance with the identifier, comparing, by the processing system, the identifier with a plurality of identifiers to determine that the communication device is authorized to access data, resulting in an authorization determination, and transmitting, by the processing system, the data to the communication device based on the authorization determination. Other embodiments are disclosed.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: Aspects of the subject disclosure may include, for example, receiving, by a processing system including a processor that is operative in a first communication network, a certificate from a communication device that is operative in a second communication network, extracting, by the processing system, an identifier of the communication device from the certificate, authenticating, by the processing system, the communication device in accordance with the identifier, comparing, by the processing system, the identifier with a plurality of identifiers to determine that the communication device is authorized to access data, resulting in an authorization determination, and transmitting, by the processing system, the data to the communication device based on the authorization determination. Other embodiments are disclosed.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.

Abstract: The present disclosure relates to deuterated forms of oxytocin, carbetocin and analogs thereof. The disclosed deuterated compounds may have similar biochemical potency and selectivity as the parent compound, and, in select instances, the selective deuteration may enable substantial benefits to their overall therapeutic profile, such as reduced adverse side effects with a decreased metabolic liability, extended pharmacological effective life, enhanced subject compliance, and/or may also decrease population pharmacokinetic variability. The present disclosure also includes pharmaceutical compositions of deuterated compounds, which may be used to treat various diseases and conditions.

Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.

Abstract: The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.

Abstract: The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Abstract: Aspects of the subject disclosure may include, for example, determining a compatibility of the mobile station with a 3GPP IMS architecture. In response to determining that the mobile station is compatible with the 3GPP IMS architecture, a transfer is facilitated of the machine-type communication message to the mobile station via a network element of an IMS network core. In response to determining that the mobile station is not compatible with the 3GPP IMS architecture a forwarding is facilitated of the machine-type communication message to a machine-type communication interworking function associated with the mobile station, wherein the machine-type communication interworking function facilitates a directing of the machine-type communication message to the mobile station via an SGs interface of a mobility management entity of an evolved packet core of a 3GPP long term evolution network. Other embodiments are disclosed.

Abstract: Aspects of the subject disclosure may include, for example, determining a compatibility of the mobile station with a 3GPP IMS architecture. In response to determining that the mobile station is compatible with the 3GPP IMS architecture, a transfer is facilitated of the machine-type communication message to the mobile station via a network element of an IMS network core. In response to determining that the mobile station is not compatible with the 3GPP IMS architecture a forwarding is facilitated of the machine-type communication message to a machine-type communication interworking function associated with the mobile station, wherein the machine-type communication interworking function facilitates a directing of the machine-type communication message to the mobile station via an SGs interface of a mobility management entity of an evolved packet core of a 3GPP long term evolution network. Other embodiments are disclosed.

Abstract: An apparatus and method for sub-page extended page table protection. For example, one embodiment of an apparatus comprises: a page miss handler to perform a page walk using a guest physical address (GPA) and to detect whether a page identified with the GPA is mapped with sub-page permissions; a sub-page control storage to store at least one GPA and other data related to a sub-page; the page miss handler to determine whether the GPA is programmed in the sub-page control storage; and the page miss handler to send a translation to a translation lookaside buffer (TLB) with a sub-page protection indication set to cause a matching of the sub-page control storage when an access matches a TLB entry with sub-page protection indication.

Abstract: Aspects of the subject disclosure may include, for example, identifying a machine-type communication message directed to a mobile station and determining a compatibility of the mobile station with a 3GPP IMS architecture. In response to determining that the mobile station is compatible with the 3GPP IMS architecture, a forwarding is facilitated of the machine-type communication message to the mobile station via a network element of an IMS network core. In response to determining that the mobile station is not compatible with the 3GPP IMS architecture a forwarding is facilitated of the machine-type communication message to a machine-type communication, interworking function associated with the mobile station, wherein the machine-type communication, interworking function facilitates a directing of the machine-type communication message to the mobile station via an SGs interface of a mobility management entity of an evolved packet core of a 3GPP long term evolution network. Other embodiments are disclosed.